by Matthias Burel | Oct 26, 2023 | Clinical Trials
RationalePatients receiving intensive therapies for hematological malignancies, such as chimeric antigen receptor (CAR) T-cell therapy or autologous hematopoietic stem cell transplantation (HSCT), frequently experience adverse effects caused by high-dose chemotherapy,...
by Matthias Burel | Oct 25, 2023 | Clinical Trials
Rationale Sepsis is a life-threatening condition arising from a dysregulated immune response to infection, leading to tissue damage, organ failure, and potentially death. Delayed diagnosis significantly increases morbidity and mortality. The Global Burden of Disease...
by Matthias Burel | Oct 24, 2023 | Clinical Trials
Rationale Patients with haematological malignancies undergoing inpatient treatment, such as immunochemotherapy or stem cell transplantation, are at increased risk for rapid clinical deterioration. Complications like cytokine release syndrome (CRS) and immune effector...
by Matthias Burel | Oct 23, 2023 | Clinical Trials
Rationale Wearable devices are increasingly used to monitor physical activity in clinical and research settings, but their accuracy in children remains under-evaluated. The ActiGraph accelerometer is widely regarded as the gold standard for measuring physical activity...
by Matthias Burel | Oct 22, 2023 | Clinical Trials
Rationale Peak oxygen uptake (VO₂ max) is a key measure of cardiorespiratory fitness, yet its assessment typically requires maximal exertion testing with expensive equipment in a hospital setting. This limits routine monitoring and early detection of fitness-related...
